Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-18

AUTHORS

Lixin Guo, Li Li, Qiurong Yu, Na Wang, Jun Chen, Zhiquan Wang, Yuchen Ding

ABSTRACT

BackgroundTRUST-CHN is a prospective, post-marketing safety study in patients with type 2 diabetes mellitus (T2DM) in China to evaluate the safety and effectiveness of dulaglutide in real-world clinical practice. We report here the study design and baseline characteristics of enrolled patients.MethodsThe study design was described, and baseline data were analyzed, including demographic characteristics, T2DM duration, comorbidities, dulaglutide treatment patterns, and concomitant medications.ResultsFor the present analysis of this ongoing study, data were collected from January 2020 to November 2021. A total of 3313 patients were enrolled, of whom 3294 patients were included in the safety analysis. In total, 1047 patients had a prior history of dulaglutide use before being enrolled in the study. The mean (standard deviation [SD]) age of study subjects was 50.1 (13.2) years, 85.1% were aged < 65 years; 67.9% were male, and 35.9% had an education of university level or higher. Mean (SD) duration of T2DM was 6.4 (6.7) years. Baseline mean (SD) glycated hemoglobin was 8.8% (2.2%), and mean (SD) body mass index was 28.1 (4.1) kg/m2. A total of 2867 (87%) patients had at least one comorbidity, the most frequently reported of which were overweight/obesity (87.1%), hyperlipidemia (50.5%), hypertension (47.9%), diabetic neuropathy (18.9%), and coronary artery disease (15.7%). Almost all (99.7%) patients were treated with 1.5 mg dulaglutide; at baseline, 24.8% were treated with this medication as monotherapy and 75.2% in combination therapy with other medications, including metformin (42.3%), sodium glucose co-transporter2 inhibitor (26.7%), insulin (18.3%), α-glucosidase inhibitor (13.1%), sulfonylurea (5.3%), dipeptidyl peptidase 4 inhibitor (4.4%), glucagon-like peptide 1 receptor agonist (2.7%), and thiazolidinedione (2.4%).ConclusionThe present analysis revealed real-world baseline characteristics of patients with T2DM in China who use dulaglutide enrolled in TRUST-CHN. These data will enable further exploration of the characteristics of patients with T2DM in China and provide an insight on the current use of dulaglutide in clinical practice. More... »

PAGES

1231-1244

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01268-2

DOI

http://dx.doi.org/10.1007/s13300-022-01268-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147961996

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35583797


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guo", 
        "givenName": "Lixin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Ningbo First Hospital, Zhejiang, China", 
          "id": "http://www.grid.ac/institutes/grid.416271.7", 
          "name": [
            "Department of Endocrinology, Ningbo First Hospital, Zhejiang, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Changshu Second People\u2019s Hospital, Jiangsu, China", 
          "id": "http://www.grid.ac/institutes/grid.440299.2", 
          "name": [
            "Department of Endocrinology, Changshu Second People\u2019s Hospital, Jiangsu, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Qiurong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Na", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.268099.c", 
          "name": [
            "Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Jun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Zhiquan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ding", 
        "givenName": "Yuchen", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-020-00804-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1126593766", 
          "https://doi.org/10.1007/s13300-020-00804-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0646-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117299789", 
          "https://doi.org/10.1007/s13300-019-0646-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-020-00839-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128395219", 
          "https://doi.org/10.1007/s13300-020-00839-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01079-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138437570", 
          "https://doi.org/10.1007/s13300-021-01079-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-18", 
    "datePublishedReg": "2022-05-18", 
    "description": "BackgroundTRUST-CHN is a prospective, post-marketing safety study in patients with type 2\u00a0diabetes mellitus (T2DM) in China to evaluate the safety and effectiveness of dulaglutide in real-world clinical practice. We report here the study design and baseline characteristics of enrolled patients.MethodsThe study design was described, and baseline data were analyzed, including demographic characteristics, T2DM duration, comorbidities, dulaglutide treatment patterns, and concomitant medications.ResultsFor the present analysis of this ongoing study, data were collected from January 2020 to November 2021. A total of 3313 patients were enrolled, of whom 3294 patients were included in the safety analysis. In total, 1047 patients had a prior history of dulaglutide use before being enrolled in the study. The mean (standard deviation [SD]) age of study subjects was 50.1\u00a0(13.2)\u00a0years, 85.1% were aged\u2009<\u200965\u00a0years; 67.9% were male, and 35.9% had an education of university level or higher. Mean (SD) duration of T2DM was 6.4 (6.7) years. Baseline mean (SD) glycated hemoglobin was 8.8% (2.2%), and mean (SD) body mass index was 28.1 (4.1) kg/m2. A total of 2867\u00a0(87%) patients had at least one comorbidity, the most frequently reported of which were overweight/obesity (87.1%), hyperlipidemia (50.5%), hypertension (47.9%), diabetic neuropathy (18.9%), and coronary artery disease (15.7%). Almost all (99.7%) patients were treated with 1.5\u00a0mg dulaglutide; at baseline, 24.8% were treated with this medication as monotherapy and 75.2% in combination therapy with other medications, including metformin (42.3%), sodium glucose co-transporter2 inhibitor (26.7%), insulin (18.3%), \u03b1-glucosidase inhibitor (13.1%), sulfonylurea (5.3%), dipeptidyl peptidase 4 inhibitor (4.4%), glucagon-like peptide 1 receptor agonist (2.7%), and thiazolidinedione (2.4%).ConclusionThe present analysis revealed real-world baseline characteristics of patients with T2DM in China who use dulaglutide enrolled in TRUST-CHN. These data will enable further exploration of the characteristics of patients with T2DM in China and provide an insight on the current use of dulaglutide in clinical practice.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01268-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "post-marketing safety studies", 
      "baseline characteristics", 
      "study design", 
      "glucagon-like peptide-1 receptor agonists", 
      "clinical practice", 
      "sodium glucose co-transporter2 (SGLT2) inhibitors", 
      "peptide-1 receptor agonists", 
      "dipeptidyl peptidase-4 inhibitors", 
      "real-world clinical practice", 
      "safety studies", 
      "characteristics of patients", 
      "overweight/obesity", 
      "coronary artery disease", 
      "peptidase-4 inhibitors", 
      "body mass index", 
      "MethodsThe study design", 
      "T2DM duration", 
      "concomitant medications", 
      "diabetic neuropathy", 
      "diabetes mellitus", 
      "treatment patterns", 
      "artery disease", 
      "mass index", 
      "mean age", 
      "combination therapy", 
      "mean duration", 
      "receptor agonist", 
      "dulaglutide", 
      "prior history", 
      "patients", 
      "study subjects", 
      "T2DM", 
      "type 2", 
      "baseline mean", 
      "medications", 
      "\u03b1-glucosidase inhibitors", 
      "demographic characteristics", 
      "baseline data", 
      "comorbidities", 
      "ongoing studies", 
      "inhibitors", 
      "current use", 
      "total", 
      "duration", 
      "further exploration", 
      "years", 
      "hypertension", 
      "monotherapy", 
      "mellitus", 
      "hyperlipidemia", 
      "neuropathy", 
      "obesity", 
      "metformin", 
      "thiazolidinediones", 
      "therapy", 
      "agonists", 
      "sulfonylureas", 
      "insulin", 
      "disease", 
      "study", 
      "present analysis", 
      "baseline", 
      "hemoglobin", 
      "age", 
      "subjects", 
      "safety", 
      "safety analysis", 
      "data", 
      "use", 
      "practice", 
      "index", 
      "levels", 
      "history", 
      "analysis", 
      "characteristics", 
      "m2", 
      "patterns", 
      "effectiveness", 
      "education", 
      "China", 
      "means", 
      "design", 
      "insights", 
      "exploration", 
      "university level"
    ], 
    "name": "Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)", 
    "pagination": "1231-1244", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147961996"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01268-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35583797"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01268-2", 
      "https://app.dimensions.ai/details/publication/pub.1147961996"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_929.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01268-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01268-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01268-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01268-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01268-2'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      114 URIs      102 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01268-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N45706ca16a644f16a19988ccc7950b47
4 schema:citation sg:pub.10.1007/s13300-019-0646-y
5 sg:pub.10.1007/s13300-020-00804-2
6 sg:pub.10.1007/s13300-020-00839-5
7 sg:pub.10.1007/s13300-021-01079-x
8 schema:datePublished 2022-05-18
9 schema:datePublishedReg 2022-05-18
10 schema:description BackgroundTRUST-CHN is a prospective, post-marketing safety study in patients with type 2 diabetes mellitus (T2DM) in China to evaluate the safety and effectiveness of dulaglutide in real-world clinical practice. We report here the study design and baseline characteristics of enrolled patients.MethodsThe study design was described, and baseline data were analyzed, including demographic characteristics, T2DM duration, comorbidities, dulaglutide treatment patterns, and concomitant medications.ResultsFor the present analysis of this ongoing study, data were collected from January 2020 to November 2021. A total of 3313 patients were enrolled, of whom 3294 patients were included in the safety analysis. In total, 1047 patients had a prior history of dulaglutide use before being enrolled in the study. The mean (standard deviation [SD]) age of study subjects was 50.1 (13.2) years, 85.1% were aged < 65 years; 67.9% were male, and 35.9% had an education of university level or higher. Mean (SD) duration of T2DM was 6.4 (6.7) years. Baseline mean (SD) glycated hemoglobin was 8.8% (2.2%), and mean (SD) body mass index was 28.1 (4.1) kg/m2. A total of 2867 (87%) patients had at least one comorbidity, the most frequently reported of which were overweight/obesity (87.1%), hyperlipidemia (50.5%), hypertension (47.9%), diabetic neuropathy (18.9%), and coronary artery disease (15.7%). Almost all (99.7%) patients were treated with 1.5 mg dulaglutide; at baseline, 24.8% were treated with this medication as monotherapy and 75.2% in combination therapy with other medications, including metformin (42.3%), sodium glucose co-transporter2 inhibitor (26.7%), insulin (18.3%), α-glucosidase inhibitor (13.1%), sulfonylurea (5.3%), dipeptidyl peptidase 4 inhibitor (4.4%), glucagon-like peptide 1 receptor agonist (2.7%), and thiazolidinedione (2.4%).ConclusionThe present analysis revealed real-world baseline characteristics of patients with T2DM in China who use dulaglutide enrolled in TRUST-CHN. These data will enable further exploration of the characteristics of patients with T2DM in China and provide an insight on the current use of dulaglutide in clinical practice.
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N3ed80ca402cf4b60888b2834c735d575
14 Nd59c0c7aea8e4efca74a12ca2c4973b0
15 sg:journal.1044057
16 schema:keywords China
17 MethodsThe study design
18 T2DM
19 T2DM duration
20 age
21 agonists
22 analysis
23 artery disease
24 baseline
25 baseline characteristics
26 baseline data
27 baseline mean
28 body mass index
29 characteristics
30 characteristics of patients
31 clinical practice
32 combination therapy
33 comorbidities
34 concomitant medications
35 coronary artery disease
36 current use
37 data
38 demographic characteristics
39 design
40 diabetes mellitus
41 diabetic neuropathy
42 dipeptidyl peptidase-4 inhibitors
43 disease
44 dulaglutide
45 duration
46 education
47 effectiveness
48 exploration
49 further exploration
50 glucagon-like peptide-1 receptor agonists
51 hemoglobin
52 history
53 hyperlipidemia
54 hypertension
55 index
56 inhibitors
57 insights
58 insulin
59 levels
60 m2
61 mass index
62 mean age
63 mean duration
64 means
65 medications
66 mellitus
67 metformin
68 monotherapy
69 neuropathy
70 obesity
71 ongoing studies
72 overweight/obesity
73 patients
74 patterns
75 peptidase-4 inhibitors
76 peptide-1 receptor agonists
77 post-marketing safety studies
78 practice
79 present analysis
80 prior history
81 real-world clinical practice
82 receptor agonist
83 safety
84 safety analysis
85 safety studies
86 sodium glucose co-transporter2 (SGLT2) inhibitors
87 study
88 study design
89 study subjects
90 subjects
91 sulfonylureas
92 therapy
93 thiazolidinediones
94 total
95 treatment patterns
96 type 2
97 university level
98 use
99 years
100 α-glucosidase inhibitors
101 schema:name Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)
102 schema:pagination 1231-1244
103 schema:productId N32087acba41c4fdfb6ca126136f0fc5c
104 N3940b72418ef4e10be1b6b2855a0b017
105 N819a1e1595ae485bb27addbcff21594b
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147961996
107 https://doi.org/10.1007/s13300-022-01268-2
108 schema:sdDatePublished 2022-08-04T17:10
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher Nfa6b2068fb534b7c90db1d16c4c4c722
111 schema:url https://doi.org/10.1007/s13300-022-01268-2
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N1b28be699371471c8165873a9332f44c rdf:first Nc5538c125af94ba2b7ed3e48551a704d
116 rdf:rest Ncba318a5bc4842dba0dc4391d01bf6c4
117 N1ca6ea9a650b40c7bc5f40feaa774569 rdf:first N76699e72aac8421580132bfcd3ce2ab1
118 rdf:rest N698fbf353b3d4d60a02b5d25410e767e
119 N1f879a1ff915495b8dbf8499d08f57d8 schema:affiliation grid-institutes:grid.506261.6
120 schema:familyName Guo
121 schema:givenName Lixin
122 rdf:type schema:Person
123 N2be48690a3a245b892bdcd1089660aae schema:affiliation grid-institutes:None
124 schema:familyName Ding
125 schema:givenName Yuchen
126 rdf:type schema:Person
127 N32087acba41c4fdfb6ca126136f0fc5c schema:name pubmed_id
128 schema:value 35583797
129 rdf:type schema:PropertyValue
130 N3940b72418ef4e10be1b6b2855a0b017 schema:name doi
131 schema:value 10.1007/s13300-022-01268-2
132 rdf:type schema:PropertyValue
133 N3ed80ca402cf4b60888b2834c735d575 schema:volumeNumber 13
134 rdf:type schema:PublicationVolume
135 N45706ca16a644f16a19988ccc7950b47 rdf:first N1f879a1ff915495b8dbf8499d08f57d8
136 rdf:rest N708aa5a9ec05436a929809ac28ed675b
137 N4fc1f0d077fb483ab080cdc7739ad344 schema:affiliation grid-institutes:grid.416271.7
138 schema:familyName Li
139 schema:givenName Li
140 rdf:type schema:Person
141 N698fbf353b3d4d60a02b5d25410e767e rdf:first Nb419f65dbc054118b4a430cdc4a21b99
142 rdf:rest Nc0cafd67c956467cb29bc07c37ec8348
143 N708aa5a9ec05436a929809ac28ed675b rdf:first N4fc1f0d077fb483ab080cdc7739ad344
144 rdf:rest N1b28be699371471c8165873a9332f44c
145 N76699e72aac8421580132bfcd3ce2ab1 schema:affiliation grid-institutes:grid.268099.c
146 schema:familyName Chen
147 schema:givenName Jun
148 rdf:type schema:Person
149 N819a1e1595ae485bb27addbcff21594b schema:name dimensions_id
150 schema:value pub.1147961996
151 rdf:type schema:PropertyValue
152 Nb419f65dbc054118b4a430cdc4a21b99 schema:affiliation grid-institutes:None
153 schema:familyName Wang
154 schema:givenName Zhiquan
155 rdf:type schema:Person
156 Nbc55261c2f494ca4badac1457b46e3f0 schema:affiliation grid-institutes:None
157 schema:familyName Wang
158 schema:givenName Na
159 rdf:type schema:Person
160 Nc0cafd67c956467cb29bc07c37ec8348 rdf:first N2be48690a3a245b892bdcd1089660aae
161 rdf:rest rdf:nil
162 Nc5538c125af94ba2b7ed3e48551a704d schema:affiliation grid-institutes:grid.440299.2
163 schema:familyName Yu
164 schema:givenName Qiurong
165 rdf:type schema:Person
166 Ncba318a5bc4842dba0dc4391d01bf6c4 rdf:first Nbc55261c2f494ca4badac1457b46e3f0
167 rdf:rest N1ca6ea9a650b40c7bc5f40feaa774569
168 Nd59c0c7aea8e4efca74a12ca2c4973b0 schema:issueNumber 6
169 rdf:type schema:PublicationIssue
170 Nfa6b2068fb534b7c90db1d16c4c4c722 schema:name Springer Nature - SN SciGraph project
171 rdf:type schema:Organization
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
176 schema:name Clinical Sciences
177 rdf:type schema:DefinedTerm
178 sg:journal.1044057 schema:issn 1869-6953
179 1869-6961
180 schema:name Diabetes Therapy
181 schema:publisher Springer Nature
182 rdf:type schema:Periodical
183 sg:pub.10.1007/s13300-019-0646-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1117299789
184 https://doi.org/10.1007/s13300-019-0646-y
185 rdf:type schema:CreativeWork
186 sg:pub.10.1007/s13300-020-00804-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126593766
187 https://doi.org/10.1007/s13300-020-00804-2
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s13300-020-00839-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128395219
190 https://doi.org/10.1007/s13300-020-00839-5
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s13300-021-01079-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1138437570
193 https://doi.org/10.1007/s13300-021-01079-x
194 rdf:type schema:CreativeWork
195 grid-institutes:None schema:alternateName Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China
196 Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
197 schema:name Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China
198 Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
199 rdf:type schema:Organization
200 grid-institutes:grid.268099.c schema:alternateName Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China
201 schema:name Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China
202 rdf:type schema:Organization
203 grid-institutes:grid.416271.7 schema:alternateName Department of Endocrinology, Ningbo First Hospital, Zhejiang, China
204 schema:name Department of Endocrinology, Ningbo First Hospital, Zhejiang, China
205 rdf:type schema:Organization
206 grid-institutes:grid.440299.2 schema:alternateName Department of Endocrinology, Changshu Second People’s Hospital, Jiangsu, China
207 schema:name Department of Endocrinology, Changshu Second People’s Hospital, Jiangsu, China
208 rdf:type schema:Organization
209 grid-institutes:grid.506261.6 schema:alternateName Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China
210 schema:name Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...